Anti-CD3e [Visilizumab (HuM291)]

AB02390-10.3-BT
ApplicationsFlow Cytometry
Product group Antibodies
ReactivityHuman, Primate
TargetCD3E
Overview
- SupplierAbsolute Antibody
- Product NameAnti-CD3e [Visilizumab (HuM291)]
- Delivery Days Customer9
- Antibody SpecificityThis antibody recognises the human CD3 epsilon. This antibody also competes with OKT3 (Muromonab) for binding site on the human T cells suggesting that they bind overlapping or closely spaced epitopes.
- Application Supplier NoteThis antibody is derived from its a murine parent antibody called M291. HuM291 was significantly less mitogenic to T cells in vitro as compared to OKT3 and induced the release of much lower levels of the cytokines tumor necrosis factor-alpha, interferon-gamma, and interleukin-10. HuM291 still retained the ability to modulate the CD3 complex and inhibit the mixed lymphocyte reaction. This antibody competes with OKT3 for binding to human T cells, which was detected using flow cytometry (PMID: 10480417). In vitro studies using chimpanzee peripheral blood mononuclear cells (PBMCs), HuM291 was reported to be less mitogenic than OKT3 and effectively depleted peripheral T cells without eliciting clinical signs of cytokine release syndrome, and recovered T cells were functionally normal (PMID: 10480415). Phase 1 trial of HuM291 in patients receiving renal allografts suggested that it was well tolerated and rapidly depleted circulating T cells in a dose-dependent manner and was associated with only mild to moderate symptoms of cytokine release (PMID: 11152101). Treatment with visilizumab (HuM291) in severe steroid-refractory ulcerative colitis induced symptomatic response and clinical response (PMID: 19714757). The (99m)Tc labeled version of this antibody is also recommended for imaging of human T cells and study of human T-lymphocyte trafficking and lymphocytic infiltration of tissues and organs (PMID: 19759100). This antibody is also reported to have some activity in advanced glucocorticoid-refractory acute graft-versus-host disease (GVHD) (PMID: 11929757).
- ApplicationsFlow Cytometry
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone IDVisilizumab (HuM291)
- Gene ID916
- Target nameCD3E
- Target descriptionCD3e molecule
- Target synonymsCD3e antigen, epsilon polypeptide (TiT3 complex); CD3e molecule, epsilon (CD3-TCR complex); CD3-epsilon; IMD18; T3E; T-cell antigen receptor complex, epsilon subunit of T3; T-cell surface antigen T3/Leu-4 epsilon chain; T-cell surface glycoprotein CD3 epsilon chain; TCRE
- HostHuman
- IsotypeIgG1
- Protein IDP07766
- Protein NameT-cell surface glycoprotein CD3 epsilon chain
- ReactivityHuman, Primate
- Storage Instruction-20°C,2°C to 8°C
- UNSPSC12352203